Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 1,507 shares at $2.12 ($3K) on 2012-11-28, disclosed to the SEC on 2012-11-30.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.12 | 100 | $212 | 6.6% |
| 2 | $2.12 | 300 | $636 | 19.8% |
| 3 | $2.13 | 100 | $213 | 6.6% |
| 4 | $2.13 | 1,000 | $2K | 66.4% |
| 5 | $2.14 | 7 | $15 | 0.5% |
| Total | $2.13 avg | 1,507 |
| $3K |
| 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-20 | $23K | — | Filing → |